product name BV-6
References: Hum Reprod. 2015 Jan;30(1):149-58; J Thorac Oncol. 2011 Nov;6(11):1801-9.
1205.57
Formula
C70H96N10O8.xCF3COOH
CAS No.
1001600-56-1(free base)
Storage
-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)
DMSO: 100 mg/mL (82.9 mM)
Water: 25 mg/mL (20.73 mM)
Ethanol: 100 mg/mL (82.9 mM)
Solubility (In vivo)
Chemical Name
N,N-(hexane-1,6-diyl)bis(1-{(2S)-2-cyclohexyl-2-[(N-methyl-L-alanyl)amino]acetyl}-L-prolyl-beta-phenyl-L-phenylalaninamide):trifluoroacetic acid(1:x)
other peoduct :
| BV6 inhibits the cell viability of HCC193 NSCLC cells with IC50 of 7.2 μM, induces apoptosis in both HCC193 and H460 cell lines, and also significantly enhances the radiosensitivity of these cell lines through activation of cleaved caspase-8 and cleaved caspase-9, respectively. In immature dendritic cells, BV-6 treatment results in moderate activation of the classical NF-kB pathway. Furthermore, BV-6 increases CIK cell-mediated lysis of hematological (H9, THP-1, and Tanoue) and solid malignancies (RH1, RH30, and TE671). BV-6 also enhances apoptosis of peripheral blood mononuclear cells and most notably has an inhibitory effect on immune cells limiting their cytotoxic potential | |
|---|---|
| In Vivo | |
| Animal model | |
| Formulation & Dosage | |
| References | [1] Li W, et al. J Thorac Oncol. 2011, 6(11), 1801-1809. |
